How I Invest with David Weisburd
E193: GLP-1s, AI & the End of Sick Care: The Next $10B Health Tech Giant
30 Jul 2025
What if your healthcare wasn't about just treating sickness, but maximizing your potential? In today's episode on How I Invest, I spoke with Dr. Cameron Sepah, founder and CEO of Maximus, a performance medicine company pioneering a new paradigm in healthcare. Cameron previously helped build Omada Health, now a billion-dollar public company, and coined the term “digital therapeutics.” Now he's productized his unique medical expertise into a next-gen men's health platform. We talked about the evolution of performance medicine, why testosterone and GLP-1s are changing how Americans manage their health, and how AI is reshaping clinical decision-making. We also dug deep into the personal and systemic failures of the traditional healthcare model — and what the next 10 years will look like as proactive medicine goes mainstream.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from How I Invest with David Weisburd
Transcribed and ready to explore now
E170: How an AI Agent Is Outperforming VCs w/Andrew D’Souza
04 Jun 2025
How I Invest with David Weisburd
E169: How to Build an Enduring Private Equity Franchise w/Alex Robinson
02 Jun 2025
How I Invest with David Weisburd
E168: How I Coach The Top 0.1% CEO's in Silicon Valley w/Alexis John d'Amecourt
30 May 2025
How I Invest with David Weisburd
E167: The Hardest Questions Limited Partners Ask GPs w/Stepstone’s Hunter Somerville
27 May 2025
How I Invest with David Weisburd
E166: $20 Billion CIO: Why Small Cap Stocks Have Underperformed (and why that’s unlikely to change) w/Brad Conger
23 May 2025
How I Invest with David Weisburd
E165: Hollywood Lessons on Risk, Reward, and Relationships with Alexander Ludwig
20 May 2025
How I Invest with David Weisburd